Table 2.
Multivariate analysis of liquid biomarkers
| Category | P Value | Interaction P Value |
| LDH (given all else) | 0.1408 | – |
| LDH*treatment (given all else) | – | 0.9334 |
| ctDNA (given all else) | 0.007 | – |
| ctDNA*treatment (given all else) | – | 0.3105 |
| CD4+/CD8+ ratio (given all else) | 0.043 | – |
| CD4+/CD8+ ratio*treatment (given all else) | – | 0.0131 |
| Category | Coefficient | Exponential (coefficient) | Standard Error (coefficient) | Z-Statistic | Probability > │Z│ |
| Treatment | 1.0817 | 2.9497 | 0.7279 | 1.4859 | 0.1373 |
| Stage IV M1a | –0.0846 | 0.9189 | 0.5747 | –0.1472 | 0.883 |
| Stage IV M1b | 0.5803 | 1.7865 | 0.5513 | 1.0526 | 0.2925 |
| Stage IV M1c (normal LDH) |
0.8828 | 2.4176 | 0.4899 | 1.802 | 0.0715 |
| Stage IV M1c (elevated LDH) |
1.2818 | 3.6032 | 0.5253 | 2.4403 | 0.0147 |
| Baseline CD4+/CD8+ ratio above median | 0.3695 | 1.447 | 0.1921 | 1.9236 | 0.0544 |
| Baseline ctDNA detectable | 0.6626 | 1.9399 | 0.2352 | 2.8172 | 0.0048 |
| Baseline CD4+/CD8+ ratio above median*treatment | –0.6999 | 0.4966 | 0.2848 | –2.4577 | 0.014 |
Disease stage was also included in the model, as it was a stratification factor (along with LDH level). Hypotheses were tested using likelihood ratio tests. P<0.05 indicates significant prognostic value; interaction p<0.05 indicates significant predictive value (top). From the model including all factors of interest, coefficients identified as having evidence of non-null status are shown (bottom).
CD, cluster of differentiation; ctDNA, circulating tumor DNA; LDH, lactate dehydrogenase.